Reducing paraprotein levels requires treating the underlying condition that produces them, most often a disorder of plasma cells in the bone marrow. Paraprotein (also called M-protein or monoclonal protein) is an abnormal antibody produced by a single clone of plasma cells, and the only reliable way to bring it down is to reduce or eliminate those cells. The approach depends entirely on whether you have a precancerous condition like MGUS or smoldering myeloma, or an active cancer like multiple myeloma.
Why Paraprotein Levels Matter
Paraprotein itself isn’t just a number on a lab report. These abnormal proteins circulate through your blood and get filtered by your kidneys, where they can cause direct damage to both the filtering units and the surrounding tissue. Because your kidneys receive about 20% of your heart’s blood output, they’re especially vulnerable when paraprotein levels are high. Elevated levels can also thicken your blood (a condition called hyperviscosity), leading to headaches, blurred vision, and in severe cases, stroke-like symptoms.
Doctors track paraprotein to gauge how active the underlying disease is and whether treatment is working. The International Myeloma Working Group defines a partial response as a 50% or greater reduction in paraprotein, while a very good partial response requires a 90% or greater drop. A complete response means the protein is no longer detectable on standard blood tests. These benchmarks guide every treatment decision.
When Treatment Isn’t Needed Yet
If you’ve been diagnosed with MGUS (monoclonal gammopathy of undetermined significance), your paraprotein level is typically low and stable, and active treatment isn’t usually recommended. MGUS progresses to a cancer requiring treatment in roughly 1% of patients per year. Smoldering myeloma carries a higher risk of progression but is also often monitored rather than treated immediately. In both cases, “reducing paraprotein” means watching and waiting while your doctor checks levels every few months to catch any upward trend early.
That said, there are some evidence-based steps you can take during this watchful waiting period, which are covered in the lifestyle and supplement sections below.
How Medical Treatment Lowers Paraprotein
For active multiple myeloma or other plasma cell cancers, treatment targets the abnormal plasma cells directly. Killing or suppressing these cells is what brings paraprotein down. Several classes of drugs do this through different mechanisms, and most patients receive a combination.
Proteasome Inhibitors
Proteasome inhibitors have become a cornerstone of myeloma treatment. Myeloma cells produce enormous quantities of monoclonal protein, and they rely on an internal recycling system (the proteasome) to manage the load of misfolded proteins that come with that overproduction. When a proteasome inhibitor blocks this system, defective proteins pile up inside the cell, triggering a stress response that ultimately causes the cell to self-destruct. These drugs also disrupt signaling pathways that myeloma cells depend on to survive and attach to bone marrow.
In clinical trials, patients who achieved at least a 30 to 40% reduction in M-protein after their first treatment cycle with certain drug combinations had significantly better long-term survival. The speed of paraprotein reduction in the early weeks of treatment is itself a strong predictor of outcome.
Immunotherapy
Antibody-based therapies work by flagging myeloma cells for destruction by your own immune system. One widely used approach targets a protein called CD38 on the surface of plasma cells. In heavily pretreated patients who had already tried multiple other therapies, this type of immunotherapy produced an overall response rate of about 31%, with roughly 14% of patients achieving a very good partial response or better. These numbers are notable because these patients had few remaining options.
CAR-T Cell Therapy
For patients whose myeloma has come back after several lines of treatment, CAR-T cell therapy represents a newer option. This involves collecting your own immune cells, engineering them in a lab to recognize myeloma cells, and infusing them back into your body. In one study of 84 patients with measurable disease, 92% achieved at least a partial response. The depth and speed of paraprotein reduction with CAR-T therapy can be dramatic compared to conventional approaches.
Stem Cell Transplant
High-dose chemotherapy followed by an autologous stem cell transplant (using your own stem cells) remains a standard treatment for eligible patients. In one study, 67% of patients who had a continued response after transplant achieved a deeper reduction in paraprotein than what was measured at the initial 100-day check. At their best response, 17% reached a stringent complete response, 33% a complete response, and 22% a very good partial response. The transplant doesn’t work by itself; it allows doctors to use chemotherapy doses high enough to wipe out the bone marrow, with the transplant rescuing blood cell production afterward.
Protecting Your Kidneys While Levels Are High
Regardless of where you are in treatment, keeping your kidneys safe is a priority when paraprotein is circulating in your blood. Dehydration is one of the most common and preventable causes of acute kidney injury in this setting, and the International Myeloma Foundation recommends correcting it as quickly as possible when it occurs.
If you have light chains spilling into your urine (sometimes called Bence Jones proteinuria), the general guidance is to drink enough fluids to produce about 3 liters of urine per day. That’s substantially more than most people drink normally, so it requires conscious effort. Other conditions that stress the kidneys, like high blood pressure or diabetes, need particularly close management in partnership with a kidney specialist, because paraprotein adds an extra burden your kidneys are already struggling with.
Diet and Nutrition
No diet can replace medical treatment for reducing paraprotein, but emerging evidence suggests certain nutritional factors may play a supporting role, particularly for people with MGUS or smoldering myeloma.
Vitamin D status appears to matter. Patients with severe vitamin D deficiency (blood levels below 25 nmol/L) had significantly higher M-protein levels, averaging 33 g/L compared to those with adequate vitamin D. While this doesn’t prove that taking vitamin D supplements will lower paraprotein, maintaining healthy levels is a reasonable step worth discussing with your doctor.
A pilot study in patients with elevated BMI and either MGUS or smoldering myeloma found that a whole food, plant-based diet improved biomarkers linked to myeloma progression, including insulin resistance. The diet also increased beneficial gut bacteria that produce butyrate, a short-chain fatty acid. Separately, research in myeloma patients on maintenance therapy found that higher gut bacterial diversity and butyrate levels at three months were associated with sustained minimal residual disease negativity, meaning no detectable cancer cells.
Curcumin: Promising but Preliminary
Curcumin, the active compound in turmeric, has attracted attention as a potential supplement for people with MGUS. Pilot studies found that short-term curcumin therapy at doses of 4 to 8 grams daily was associated with reductions in the ratio of free light chains in the blood, as well as lower total serum protein and urinary protein levels. Researchers have described these initial results as “very encouraging.”
However, these were small pilot studies, not large randomized trials, and some experts have urged caution about drawing firm conclusions. Curcumin is also poorly absorbed by the body, and the doses used in studies are far higher than what you’d get from cooking with turmeric. If you’re considering curcumin supplements, it’s worth knowing that the evidence is genuinely preliminary, not yet strong enough to call it a proven intervention.
What a Declining Paraprotein Level Means
When your paraprotein drops during treatment, it signals that the abnormal plasma cells are being killed or suppressed. But the speed and depth of that decline tell your doctor more than the direction alone. A rapid, steep drop in the first cycle or two of treatment generally predicts better long-term outcomes. Conversely, if paraprotein barely budges or stabilizes at a plateau, your treatment team may consider switching to a different regimen or adding another drug.
Even after achieving a complete response where paraprotein is undetectable on standard tests, most patients continue some form of maintenance therapy to keep the remaining cancer cells suppressed. The goal has shifted in recent years from simply reducing paraprotein to achieving minimal residual disease negativity, where even the most sensitive tests can’t find myeloma cells in the bone marrow. Patients who reach this deeper level of response tend to stay in remission longer.